News >

Margetuximab Improves PFS in Metastatic HER2+ Breast Cancer

Gina Columbus @ginacolumbusonc
Published: Wednesday, Feb 06, 2019

Hope Rugo, MD

Hope Rugo, MD

Margetuximab in combination with chemotherapy improved progression-free survival (PFS) compared with trastuzumab (Herceptin) and chemotherapy in heavily pretreated patients with metastatic HER2-positive breast cancer, according to findings from the phase III SOPHIA trial (NCT02492711).1

Results showed that patients in the margetuximab arm experienced a 24% reduction in the risk of disease progression or death versus patients in the trastuzumab arm (HR, 0.76; P = .033). Regarding safety, MacroGenics, the developer of the investigational immune-enhancing monoclonal antibody, noted that the margetuximab combination demonstrated acceptable safety and tolerability versus the trastuzumab regimen.

Also, in the trial, approximately 85% of patients in the study were CD16A (FcγRIIIa) 158F allele carriers, which was previously linked with diminished clinical response to trastuzumab and other antibodies. In this subgroup, there was a 32% reduction in the risk of disease progression or death for patients the margetuximab arm versus the trastuzumab arm (HR, 0.68; P = .005).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication